Efficacy and Safety of EUS-guided radiofrequency ablation for hepaticopancreatic neoplasms

未提供0 个研究点目标入组 20 人开始时间: 2025年4月4日最近更新: 2025年4月11日

试验速览

暂无简介。

•1 Individuals aged 18 years or older at the time of consent acquisition.
•2 Individuals who have provided written consent based on their own free will after receiving sufficient explanation and fully understanding the details of the study.
•3 The pancreatic tumor planned for treatment must be confirmed by pathological examination as one of the following:
•NEN with Grade 1(WHO2017 classification), or Solid Pseudopapillary Neoplasm(SPN).
•Note. A pathological examination is not required for liver tumors if blood tests and imaging findings are typical of
•hepatocellular carcinoma(HCC).
•4 Tumor diameter must be within 20 mm, as confirmed by contrast enhanced CT.
•5 For functional NEN, the tumor must be an insulinoma.

•1 History of allergy to contrast agents (iodine).
•2 Presence of a cardiac pacemaker.
•3 Distance to the main pancreatic duct is less than 2 mm on imaging (for pancreatic tumors).
•4 Lymph node metastasis or distant organ metastasis suspected outside the treatment area on imaging.
•5 Coagulation factor PT (prothrombin time) of 50% or less, or an INR (international normalized ratio) of 1.5 or higher.
•6 Platelet count of 50.000 per microliter or less.
•7 Creatinine clearance (eGFR) of less than 30 mL/min/1.73m
•8 Oral administration of two or more antithrombotic drugs.
•9 ECOG Performance Status (PS) of 2 to
•10 Child Pugh classification of C (for liver tumors).
•11 Cases where treatment is possible with a percutaneous approach (for liver tumors).
•12 Pregnancy or the possibility of being pregnant.
•13 Other patients deemed unsuitable for the study by the principal investigator or coinvestigators.

Proportion of complete tumor ablation (at 1 and 6 months)

发起方

未提供